NCT06106802View on ClinicalTrials.gov

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions

Non-Small Cell Lung Cancer Metastatic

Interventions

DRUG

Lazertinib

Lazertinib 240mg/day

DRUG

Tepotinib

Tepotinib 500mg/day

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER